Coronavirus Update: Pfizer Pledges To Double US Vaccine Output
Plus: Novavax Signs Pact For Equitable Vaccine Access
A round-up of the latest developments, including Celltrion’s new antibody cocktail and SK Biosience and Novavax expanding their collaboration.
You may also be interested in...
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.
An EUA would carve out a market advantage, although Moderna should be releasing similar data soon for its COVID-19 vaccine.
A round up of COVID-19 developments, including the CDC advising that it is "prudent" to start testing variant vaccines in case the South African B.1.351 strain gains a foothold in the US.